open image in gallery Injection pens and boxes of Novo Nordisk’s weight-loss drug Wegovy are seen in November 2023 ... Both drugs are different versions of the diabetes treatments Mounjaro and Ozempic ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...

After a stellar FY24 performance, Natco Pharma’s stock has taken a hit. What’s next for the company as it faces crucial ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head ...

On Nov. 26, the Biden administration announced a plan to require Medicare and Medicaid to cover weight loss medications like ...